Mesoblast Ltd has released a press release.
GVHD Day 28 Results Presentation
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
In the deck
Earlier from Mesoblast
- Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial
- Appendix 3B with prospectus
- Mesoblast Receives RMAT For LVAD Heart Failure Patients
- Mesoblasts P3 GVHD Trial Completes Enrollment
- Mesoblast Grants TiGenix License For Treatment of Fistulae
Later from Mesoblast
- MSB Enters Into $75 Million Non-Dilutive Credit Facility
- Partnership For Allogeneic Cell-based Cancer Immunotherapies
- Key Day 100 Survival Results In P3 GvHD Trial
- MSB Enters Into US$50M Financing With NovaQuest Capital
- MSB Enters Into Cardiovascular Alliance For China With Tasly
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast